Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
huMAb OX40L · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| huMAb OX40L | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| huMAb OX40L | DRUG | Intravenous repeating dose |
| placebo | DRUG | Intravenous repeating dose |
Inclusion Criteria: * Weight between 50 and 125 kg * Mild, stable allergic asthma * History of episodic wheeze and shortness of breath * FEV1 at baseline ≥ 70% of the predicted value * For women of childbearing potential, agreement to use an effective means of contraception while enrolled in the st...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
huMAb OX40L is an investigational monoclonal antibody developed by Roche Holding AG for asthma. It is a human antibody designed to act on the OX40L pathway and has been studied in adults with mild allergic asthma. It remains in clinical development and is not an approved therapy.
huMAb OX40L was studied for the prevention of allergen-induced airway obstruction in adults with mild allergic asthma. The clinical work focused on whether blocking its target could reduce airway narrowing triggered by allergen exposure. It is investigational and has not been approved for asthma or any other indication.
huMAb OX40L targets OX40L, also called OX40 ligand, a molecule involved in immune cell signaling. By binding OX40L, the antibody is designed to interfere with that interaction. It is a monoclonal antibody, and the name reflects the human antibody format used against the OX40L target.
huMAb OX40L is developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor behind the clinical program for this monoclonal antibody in respiratory disease.
huMAb OX40L is in Phase 2 development. It is an investigational monoclonal antibody and is not FDA approved. The Phase 2 work in asthma has been completed, and no active trials for this asset are currently listed.
huMAb OX40L has been studied in one completed Phase 2 trial, NCT00983658, titled A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma. The trial enrolled 29 adults, was randomized, double blind, and placebo controlled.